References
- Robertson JF, Lindemann JP, Llombart-Cussac A et al. A Comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the ‘FIRST’ study. Cancer Res.70(24 Suppl.), 76s (2010).
- Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO trial (BIG 01–06/EGF 106903): a Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, December 8–12 2010.
- Gianni L, Pienkowski T, Im Y-H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized Phase II study (‘NeoSphere’). Cancer Res.70(24 Suppl.), 82s (2010).
- Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol.28(7), 1124–1130 (2010).
- Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol.28(7), 1138–1144 (2010).
- Perez E, Dirix L, Kocsis J et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2 positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized multicenter, open-label Phase 2 study. Presented at: ESMO. Milan, Italy, 8–12 October 2010.
- Sampath D, Fields C, Li G et al. Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with trastuzumab–DM1 antibody drug conjugate enhances anti-tumor activity in preclinical breast cancer models in vitro and in vivo. Cancer Res.70(24 Suppl.), 83s (2010).
- Rack B, Schindlbeck C, Andergassen U et al. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Cancer Res.70(24 Suppl.), 93s (2010).
- Pierga J-Y, Bachelot T, Delaloge S et al. High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast Patients. Cancer Res.70(24 Suppl.), 93s (2010).
- Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J. Clin. Oncol.28(28), 4307–4315 (2010).
- Gong Y, Sweet W, Duh YJ et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am. J. Clin. Pathol.131(4), 490–497 (2009).
- Loibl S, Mueller B, Von Minckwitz G et al. PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 4–8 June 2010.
- Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol.28(35), 5132–5139 (2010).
- Twelves C, Loesch D, Blum J et al. A Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 4–8 June 2010.